Thanks in part to the massive success of Novo Nordisk’s obesity drug Wegovy and its counterpart for diabetes, Ozempic, Novo Holdings’ coffers have been swelling. It now manages a huge $30bn investment fund. In a fascinating fireside chat at this year’s Optimum conference, Novo Holdings’ CEO Kasim Kutay provided a unique insight into this growing […]
The UK is in a pretty strong position when it comes to growing its life science sector – but there is undoubtedly room for improvement. That was the verdict of Professor Sir Chris Whitty, Chief Medical Officer for England, and the keynote speaker at this year’s Optimum Strategic Communications Conference, which was held on Wednesday […]
Last week, Optimum held its 15th Annual Healthcare Investor Conference – marking its crystal anniversary – and what a sparkler it was! As soon as the clock struck 12, attendees started pouring into the Wellcome Collection venue. Had they heard champagne was to be served, and didn’t want to miss out? Maybe. Did they want […]
Alchemab’s CEO Young Kwon has appeared on the leading pharma website pharmaphorum outlining the company’s revolutionary approach to antibody technology. In the podcast, Kwon outlined how Cambridge, UK-based Alchemab wants to find a new generation of antibody drugs using a novel approach. The company is searching through the entire antibody repertoire of the human body […]
